Market Overview

Morning Market Movers

Share:
Related PPHM
Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab
Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Activate Tumor Targeting Immune Cells in PD-L1 Negative NSCLC Tumors
Related EPOC
Benzinga's Volume Movers
athenahealth to Acquire Epocrates for $11.75/Share in Cash

Peregrine Pharmaceuticals (NASDAQ: PPHM) surged 39.26% to $1.88 at 9:45 am. Peregrine Pharmaceuticals provided an update from its internal review of discrepancies from its Phase II second-line non-small cell lung cancer (NSCLC) in 121 patients.

Dialogic (NASDAQ: DLGC) shares advanced 31.34% to $2.39. Dialogic shares have dropped 54.50% over the past 52 weeks, while the S&P 500 index has gained 14.51% in the same period.

Epocrates (NASDAQ: EPOC) surged 21.63% to $11.70. Epocrates agreed to be bought by athenahealth (NASDAQ: ATHN) for $11.75 per share in cash.

RF Industries (NASDAQ: RFIL) climbed 19.56% to $5.3682. For the fourth quarter, RF Industries' preliminary unaudited revenue surged 77% y/y.

Posted-In: Morning Market MoversNews Intraday Update Markets Movers

 

Related Articles (ATHN + DLGC)

Around the Web, We're Loving...

Get Benzinga's Newsletters